drugset / Trial / NCT05323149

Tranexamic Acid in Traumatic Brain Injury

NCT05323149

Phase 3 Recruiting 60 enrolled Assiut University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study, our aim is to investigate the role of tranexamic acid for modulating the inflammation in patients with traumatic brain injury (TBI).

Timeline

Start
2022-05-18
Primary completion
2027-09-10
Completion
2027-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 g

Indications